ELANE and neoplasm: Future clinical studies can assess the combination of multiple biomarkers, such as cardiac markers (troponins and BNP/NT-proBNP) and other circulating NET markers (neutrophil elastase) [35], to better understand the relationship between tumor progression and cardiotoxicity.